Regulation of HtrA2 on WT1 gene expression under imatinib stimulation and its effects on the cell biology of K562 cells

  • Authors:
    • Lixia Zhang
    • Yan Li
    • Xiaoyan Li
    • Qing Zhang
    • Shaowei Qiu
    • Qi Zhang
    • Min Wang
    • Haiyan Xing
    • Qing Rao
    • Zheng Tian
    • Kejing Tang
    • Jianxiang Wang
    • Yingchang Mi
  • View Affiliations

  • Published online on: July 20, 2017     https://doi.org/10.3892/ol.2017.6628
  • Pages: 3862-3868
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the regulation of Wilms Tumor 1 (WT1) by serine protease high-temperature requirement protein A2 (HtrA2), a member of the Htr family, in K562 cells. In addition, the study aimed to observe the effect of this regulation on cell biological functions and its associated mechanisms. Expression of WT1 and HtrA2 mRNA, and proteins following imatinib and the HtrA2 inhibitor 5‑[5‑(2‑nitrophenyl) furfuryl iodine]‑1, 3‑diphenyl‑2‑thiobarbituric acid (UCF‑101) treatment was detected with reverse transcription‑quantitative polymerase chain reaction and western blot analysis. Subsequent to treatment with drugs and UCF‑101, the proliferative function of K562 cells was detected using MTT assays, and the rate of apoptosis was detected using Annexin V with propidium iodide flow cytometry in K562 cells. The protein levels in the signaling pathway were analyzed using western blotting following treatment with imatinib and UCF‑101. In K562 cells, imatinib treatment activated HtrA2 gene at a transcription level, while the WT1 gene was simultaneously downregulated. Following HtrA2 inhibitor (UCF‑101) treatment, the downregulation of WT1 increased gradually. At the protein level, imatinib induced the increase in HtrA2 protein level and concomitantly downregulated WT1 protein level. Subsequent to HtrA2 inhibition by UCF‑101, the WT1 protein level decreased temporarily, but eventually increased. Imatinib induced apoptosis in K562 cells, but this effect was attenuated by the HtrA2 inhibitor UCF‑101, resulting in the upregulation of the WT1 protein level. However; UCF‑101 did not marke­dly change the proliferation inhibition caused by imatinib. Imatinib activated the p38 mitogen activated protein kinase (p38 MAPK) signaling pathway in K562 cells, and UCF‑101 affected the activation of imatinib in the p38 MAPK signaling pathway. Imatinib inhibited the extracellular signal‑related kinase (ERK1/2) pathway markedly and persistently, but UCF‑101 exhibited no notable effect on the inhibition of the ERK1/2 pathway. HtrA2 and its regulatory effect on WT1 may affect the sensitivity of BCR/ABL(+) cell lines to target therapy drugs through different mechanisms. Regulation of WT1 by HtrA2 occurs in K562 cells, and the regulation may affect the apoptosis of K562 cells under the stress caused by chemotherapeutic treatment. The p38 MAPK signaling pathway, which serves an important role in cell apoptosis, is a downstream pathway of this regulation.

References

1 

Apperley JF: Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia. Lancet Oncol. 8:1018–1029. 2007. View Article : Google Scholar : PubMed/NCBI

2 

Deininger M, Buchdunger E and Druker BJ: The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 105:2640–2653. 2005. View Article : Google Scholar : PubMed/NCBI

3 

Yang L, Han Y, Suarez Saiz F and Minden MD: A tumor suppressor and oncogene: The WT1 story. Leukemia. 21:868–876. 2007.PubMed/NCBI

4 

Radich J, Dai H, Mao M, Oehler V, Schelter J, Druker B, Sawyers C, Shah N, Stock W, Willman CL, et al: Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci USA. 103:2794–2799. 2006. View Article : Google Scholar : PubMed/NCBI

5 

Varma N, Anand MS, Varma S and Juneja SS: Role of hTERT and WT1 gene expression in disease progression and imatinib responsiveness of patients with BCR-ABL positive chronic myeloid leukemia. Leuk Lymphoma. 52:687–693. 2011. View Article : Google Scholar : PubMed/NCBI

6 

Otahalova E, Ullmannova-Benson V, Klamova H and Haskovec C: WT1 expression in peripheral leukocytes of patients with chronic myeloid leukemia serves for the prediction of Imatinib resistance. Neoplasma. 56:393–397. 2009. View Article : Google Scholar : PubMed/NCBI

7 

Svensson E, Vidovic K, Lassen C, Richter J, Olofsson T, Fioretos T and Gullberg U: Deregulation of the Wilms' tumour gene 1 protein (WT1) by BCR/ABL1 mediates resistance to imatinib in human leukaemia cells. Leukemia. 21:2485–2494. 2007. View Article : Google Scholar : PubMed/NCBI

8 

Kim MK, McGarry TJ, Broin OP, Flatow JM, Golden AA and Licht JD: An integrated genome screen identifies the Wnt signaling pathway as a major target of WT1. Proc Natl Acad Sci USA. 106:11154–11159. 2009. View Article : Google Scholar : PubMed/NCBI

9 

Li Y, Wang J, Li X, Jia Y, Huai L, He K, Yu P, Wang M, Xing H, Rao Q, et al: Role of the Wilms' tumor 1 gene in the aberrant biological behavior of leukemic cells and the related mechanisms. Oncol Rep. 32:2680–2686. 2014.PubMed/NCBI

10 

Li X, Li Y, Yuan T, Zhang Q, Jia Y, Li Q, Huai L, Yu P, Tian Z, Tang K, et al: Exogenous expression of WT1 gene influences U937 cell biological behaviors and activates MAPK and JAK-STAT signaling pathways. Leuk Res. 38:931–939. 2014. View Article : Google Scholar : PubMed/NCBI

11 

Hartkamp J, Carpenter B and Roberts SG: The Wilms' tumor suppressor protein WT1 is processed by the serine protease HtrA2/Omi. Mol Cell. 37:159–171. 2010. View Article : Google Scholar : PubMed/NCBI

12 

Hartkamp J and Roberts SG: HtrA2, taming the oncogenic activities of WT1. Cell Cycle. 9:2508–2514. 2010. View Article : Google Scholar : PubMed/NCBI

13 

Klupsch K and Downward J: The protease inhibitor Ucf-101 induces cellular responses independently of its known target, HtrA2/Omi. Cell Death Differ. 13:2157–2159. 2006. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

September 2017
Volume 14 Issue 3

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Zhang, L., Li, Y., Li, X., Zhang, Q., Qiu, S., Zhang, Q. ... Mi, Y. (2017). Regulation of HtrA2 on WT1 gene expression under imatinib stimulation and its effects on the cell biology of K562 cells. Oncology Letters, 14, 3862-3868. https://doi.org/10.3892/ol.2017.6628
MLA
Zhang, L., Li, Y., Li, X., Zhang, Q., Qiu, S., Zhang, Q., Wang, M., Xing, H., Rao, Q., Tian, Z., Tang, K., Wang, J., Mi, Y."Regulation of HtrA2 on WT1 gene expression under imatinib stimulation and its effects on the cell biology of K562 cells". Oncology Letters 14.3 (2017): 3862-3868.
Chicago
Zhang, L., Li, Y., Li, X., Zhang, Q., Qiu, S., Zhang, Q., Wang, M., Xing, H., Rao, Q., Tian, Z., Tang, K., Wang, J., Mi, Y."Regulation of HtrA2 on WT1 gene expression under imatinib stimulation and its effects on the cell biology of K562 cells". Oncology Letters 14, no. 3 (2017): 3862-3868. https://doi.org/10.3892/ol.2017.6628